The expressions of Ret/PTC and p53 in normal, benign and malignant thyroid lesions by Omar, Effat et al.
Final Report 
The Expressions of Ret/PTC and p53 in 
Normal, Benign and Malignant Thyroid 
Lesions 
Effat Omar, M. Madhavan, Nor Hayati Othman 
USM Short Term Grant 
304/PPSP/6151188 
1 
• J. f 
1 
' 
1) 
.. 
SAHAGIAN PENYELIDIKAN & PEMBANGUNAN 
CANSELORI 
UNIVERSITI SAINS MALAYSIA 
Laporan Akhir Projek Penyelidikan Jangka Pendek 
Nama Penyelidik: Professor (Dr.) Nor Hayati Othman 
Nama Penyelidik-Penyelidik 
Lain (Jika berkaitan) Dr. Effat Omar@ Abdul Rahman 
Assoc. Prof. M.Madhavan 
J 
USM J/P- 06 
UNI\"ER S: I l C::.-\ !1\iS ---- -· 
...., MALAYSIA I 
..... .I.!_.., , fMA 
/2_:_ -~ 1 ' 
n :.an; n n & D Pu5~t p,.11 • <; . Cln' 1'1,; Per 
2) Pusat PengajianJPusaUUnit : Pusat Pengajian Sains Perubatan 
....... ....... . ......... ······· ····· .... .. ········· ............... ....... ....... . ......... ·· ·· ····· ····· ···· 
3) Tajuk Projek: 
To Determine the Expression ofRet/PTC and P53 Expression in Normal, 
Benign and Malignant Thywid L esions 
.... ... ............ ... .... . ······ ... ..... ............................. ..... ········· ··· ··· ···· ····· ... ······ 
......... ............... .... ................................. ... ... ............ . ... .. ... ... ............ ···· ····· 
• 
4) (a) 
USM J/P..Q6 - 1 
Penemuan Projek/Abstrak 
(Perlu disediakan makluman di antara 100 - 200 perkataan di dalam Bahasa Malaysia dan Bahasa 
lnggeris. lni kemudiannya akan dimuatkan ke dalam Laporan Tahunan Sahagian Penyelidikan & 
Pembangunan sebagai satu cara untuk menyampaikan dapatan projek tuan/puan kepada pihak 
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Abstrak 
Kadar pembengkakan kelenjar tiroid setempat terutamanya Kelantan adalah tinggi. Kajian di 
Hospital USM menunjukkan yang terdapat banyak kes barah yang clikesan dalam kes-kes tiroid ini. 
Ret/PTC adalah sejenis onkogen yang agak baru ditemui yang berkaitan hanya dengan kanser papilari 
tiroid. P53 pula adalah satu 'tumour suppressor gene' yang biasanya dikesan pada barah thyroid yang 
agresif. Bagaimanapun, kaedah imunohistokimia boleh mengesan p53 pada barah yang kurang agresif. 
Kami ingin mengkaji kadar mutasi ret/PTC dan p53 didalam populasi pesakit tiroid setempat dengan 
barapan untuk mengetahui patogenesis barah tiroid dan memberikan penjelasan tentang kenapa tingginya 
kadar barah ini dikawasan ini. 
Buku pendaftaran Jabatan Patologi HUSM ditelaah untuk mengenalpasti 66 kes 'nodular 
hyperplasia' tiroid , 50 kes 'follicular adenoma' dan 53 kes barah tiroid papillary. Ujian imunohistokimia 
kemudian dijalankan keatas paraffin blok arkib kes-kes tersebut. Tisu tiroid normal dari 74 kes-kes 
tersebut digunakan sebagai control. 
Kami mendapati bahwa ekspressi ret/PTC ialah 5.4% pada normal tiroid, 18% pada 'follicular 
adenoma', 22.7% pada 'nodular hyperplasia' dan 71.7% pada kanser papillary'. Tiada kaitan antara 
expressi ret dan umur, jantina, jangkamasa penyakit, sikap agresif barah itu dan kesudahan kehidupan 
pesakit berkaitan dengan barah. Ekspressi p53 dikesan pada 1 ~~--'follicular adenoma', 16.7% 'nodular 
hyperplasia' dan 17% 'papillary carcinoma'. Sell tiroid Y~$~~!1 _tiada ekspressi p53. Seperti diatas, 
umur, jantina dan jangkamasa penyakit tidakmempengan..bi =e~spressi p53. Walaubagaimanapun, p53 
merupakan predictor yang sangat baik diatas pelanggaran :kap~!~an metastasis barah ke kelenjar limfa. 
__ --_ -~ -~=-=- ·=--~--. -
p53 juga mempunyai pengaruh atas kesudahan kehidupail peSaki.t lia.!atl tersebut. 
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pembetukan tumor tiroid tersebut. P53 pula be~~na ~agi m(!~ samada barah itu berpotesi untuk 
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menunjukkan tingkah laku agresif seperti pelanggaran kapsul dan metastasis kelenjar limfa. Ia juga 
berupaya meramal kesan barah keatas kesudahan penghidupan pesakit tersebut. 
Abstract 
Goiter is a highly prevalent problem in the local population. Studies at HUSM have found high 
percentage of papillary carcinoma within this lesion. Ret/PTC is a recently discovered oncogene which is 
solely related to papillary carcinoma. It has been proven to play a major role in the pathogenesis of this 
malignant lesion. P53 gene is a well known tumour suppressor gene, usually associated with the 
undifferentiated thyroid carcinoma. Immunohistochemistry is able to demonstrate p53 mutation in well 
differentiated thyroid carcinoma. This study aims to investigate the expression of ret and p53 in the local 
normal, benign and malignant thyroid lesions in order to shed light on the pathogenesis of papillary 
carcinoma and explain the high prevalence of this condition among the nodular hyperplasia ( multinodular 
goiter) cases. 
From the records of HUSM pathology department, archival blocks from 50 follicular adenomas, 
66 nodular hyperplasia cases and 53 papillary carcinoma cases were retrieved. They were studied by 
immunohistochemistry method for the presence of ret/PTC and p53 mutant protein within the follicular 
cells. Normal thyroid tissues from 74 of the cases were utilized as controls. 
Ret/PTC is expressed by 5.4% of normal thyroid tissue, 18% of follicular adenomas, 22.7% of 
nodular hyperplasia cases and 71.7% of papillary carcinomas. There is no statistically significant difference 
of ret expression between pure nodular hyperplasia and the ones with coexisting papillary carcinoma. 
Ret/PTC expression of papillary carcinoma is not associated ~~g_::-- gender, duration of symptoms, 
tumour aggressiveness or patients' survival outcome. ::Psi is""' e~t~ssed by 14% of follicular adenomas, 
16.7% of nodular hyperplasia and 17% of papillary_ carc~~~·~.<:>rmal· ~hyroid tissues do not harbour any 
p53 mutation. No association was found between p53 e~ressioiCOiiiodular hyperplasia with or without 
coexisting papillary carcinoma. Age, gender, duraiionof'~YJ!lp.toms-]fnd size of papillary carcinoma is not 
--~ 
·-.,-~-
related to p53 expression. However, p53 is an excellent predictor':o'rtumour lymph node metastasis and 
capsular invasion. It is also a significant prognosticator of ~~~al outcome of papillary carcinoma 
patients. 
______ .a 
-~~~ 
-~ 
...• .;;; 
.. ~ 
;~:; 
Ret/PTC mutation is highly prevalent in local papillary carcinoma with low expression in the 
benign lesions. This indicates that ret/PTC has a significant role in the pathogenesis of the papillary 
carcinoma in the local population; but does not have any- role subsequent tumour behaviour and survival 
outcome. P53 on the other hand appear to be a significant factor in predicting tumour aggressiveness and 
survival outcome. 
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Abstract 
To investigate RET and p53 expression in local thyroid lesions, in order to 
shed light on the pathogenesis of papillary carcinoma and explain the high 
prevalence of this condition among the nodular hyperplasia (multinodular 
goitre) cases. 
Archival thyroid tissue was retrieved from HUSM (Hospital Universiti Sains 
Malaysia) Pathology Department files and studied by 
immunohistochemistry for RET and p53 mutant protein. Normal tissues 
from 74 cases served as controls. 
Fifty follicular adenoma, 66 nodular hyperplasia and 53 papillary carcinoma 
cases were studied. RET was expressed in 5.4% of normal thyroid tissue, 
18% of follicular adenomas, 22.7°k of nodular hyperplasia cases and 71.7% 
of papillary carcinomas. Its expression in papillary carcinoma was not 
associated with the coexistence of nodular hyperplasia lesions. p53 was 
expressed by 17% of papillary carcinomas. No association was found 
between p53 expression of nodular hyperplasia with or without coexisting 
papillary carcinoma. p53, rather than RET, was an excellent predictor of 
tumour lymph node metastasis and capsular invasion. p53 was also a 
significant prognosticator of survival outcome. 
RET expression is highly prevalent in local papillary carcinoma, indicating 
a significant role in the pathogenesis of this tumour; with no apparent role 
in tumour behaviour and survival outcome. p53 on the other hand appears 
2 
to be a significant factor in the latter events. The two genes appear to act in 
two different pathways; the former being an initiator, and the later a 
propagator of papillary carcinoma. 
Key words: Thyroid, goitre, papillary carcinoma, Ret/PTC, p53. 
INTRODUCTION 
The development of a malignant lesion in a long-standing pre-existing 
benign condition has been documented for many tumours, including thyroid 
carcinoma. 1 
A study of 300 thyroid specimens submitted to the University Science 
Malaysia Hospital Pathology Department from 1990 until 1995 revealed that 
multinodular goitre is the most common lesion. Examination of these multinodular 
goitres, where representative sections were taken from the widest cut surface as 
well as other solid nodules (number of blocks ranged from 4 to 10 blocks per 
specimen) revealed co-existing carcinoma in 34o/o of cases.2 This is very high in 
comparison to other international series of sporadic goitre where only 4 to 17o/o of 
the glands were found to harbour carcinomas. 3 
Papillary carcinoma of the thyroid has no identifiable precursor lesion to 
date, compared to follicular carcinoma, which is linked to follicular adenoma. 4 In 
addition, the ret/PTC oncogene, which was discovered relatively recently, is 
found to be associated with only papillary carcinoma.5 Most studies have found 
that no other follicular cell tumour expresses it. 5'6'7 The ret proto-oncogene 
encodes a member of the tyrosine kinase family of trans-membrane receptors 
3 
and has been mapped to the region of chromosome 10q11.2.8•9 It consists of 21 
exons10, spanning more than 60 kb of genomic DNA and encodes five major 
mRNA species. The proto-oncogene products are expressed as polypeptides of 
1 072 and 1114 amino acid residues that differ in C-terminal amino acid 
composition. 10 The ret protein is a receptor for a glial cell line-derived 
neurotrophic factor that is normally expressed in neuroendocrine cells and also 
tumours of these cells. 5 It is not present in the normal thyroid follicular cells. 4 
Sporadic papillary carcinoma of the thyroid is associated with somatic 
rearrangement of the ret gene. 11 This type of papillary-thyroid-carcinoma (PTC) 
specific mutation was first described in a lymph node with metastatic papillary 
thyroid carcinoma.11 Consequent analyses revealed the three most frequent 
forms of ret/PTC rearrangement; known as ret/PTC-1, -2, and -3.7•12•13 
p53 is a well-studied tumour suppressor gene, located on chromosome 
17p13.1. Its mutation has been reported mainly in anaplastic carcinoma, 
frequently involving exons 5 to 8. 4 However in a recently published study 
employing immunohistochemistry, mutant p53 protein has been detected in 
papillary carcinoma, as well as in follicular carcinoma.14 
The wild-type p53 protein has a short half-life, whereas the mutated 
protein remains within the cells for a longer time, allowing detection by 
immunohistochemistry. p53 expression in papillary and follicular carcinoma has 
been correlated with aggressiveness, as evidenced by the presence of extra-
thyroidal tumour extension in p53-positive tumours. 14 
4 
The question is whether we have at last found a reliable marker 
(ret/PTC) to detect follicular cells with mutations that progress into papillary 
carcinoma. If so. then is it possible that the high incidence of papillary carcinoma 
seen in the nodular hyperplasia population is due to activation of this mt/PTC 
oncogene. 
We were also interested in whether there is any association between 
p53 and ret gene expression, and if these markers are useful in predicting a 
malignant transformation in a benign lesion. We further investigated the 
usefulness of p53 and ret/PTC in predicting aggressiveness of papillary 
carcinoma, and compared them to assess them as predictors of survival. 
The answers to these questions are important firstly in unravelling the 
pathogenesis of the papillary carcinoma in our locality and secondly in identifying 
the patients who are more likely to develop aggressive disease, making it 
possible for clinicians to tailor each patient's treatment; avoiding over or under 
treatment. 
MATERIALS AND METHODS 
Materials 
Archival blocks of thyroid tissue from 1990 until 2000, which had been 
histologically diagnosed as multinodular goitre (nodular hyperplasia), follicular 
adenoma and papillary carcinoma, were retrieved from the registry of HUSM 
Pathology Department, Kelantan, Malaysia. 
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Clinical data 
The clinical data of the patients including age, sex and race were 
recorded. Duration of symptoms for papillary carcinoma (visible neck swelling}, 
size of tumour, duration of follow-up and sutvival characteristics (tumour 
recurrence, death due to disease or other causes) were obtained from the 
patients' medical records. 
Histology 
All histologic materials from the selected cases were reviewed by one of 
the authors (E. 0.) to confirm that the diagnosis was in accordance with the 
recommendations of the World Health Organization. The presence of lymph node 
metastasis, capsular and extra-thyroidal invasion, as well as vascular and 
lymphatic invasion were determined histologically. 
Immunohistochemistry for RET 
Tissue blocks were sectioned at 3 microns thickness and applied to poly-1-
lysin pre-coated slides. Endogenous peroxidase quenching was carried out by 
incubation with 3o/o hydrogen peroxide in methanol. Immunohistochemistry for 
RET was performed using a rabbit polyclonal antibody against the carboxy 
terminal region of RET (C-19, Santa Cruz biotechnology, Santa Cruz, CA) at a 
dilution of 1: 1 00 at room temperature for 2 hours or at 4 oc for 16 hours. A 
streptavidin-avidin-biotin complex (DAKO, Denmark) detection system was used 
with diaminobenzidine employed as the substrate. The extent of staining was 
scored according to the method described in a previous study15: grade o, Oo/o; 
grade 1, <25o/o; grade 2, 25-50o/o; and grade 3, > 50%. Intensity of the staining 
6 
was also noted {low, medium and high intensity). Only cytoplasmic staining was 
noted. 
Immunohistochemistry for p53 protein 
P53 was detected using a commercial monoclonal antibody (DAKO, D0-
7) at a dilution of 1:50 incubated at room temperature for 2 hours. A streptavidin-
avidin-biotin complex (DAKO, Denmark) detection system was used with 
diaminobenzidine as the substrate. The mutant p53 is concentrated in the 
nucleus of the cells. One hundred cells were counted and the number of 
positively staining nuclei noted. Using a cut-off point of 1 o cells, the positivity was 
scored as 1+ (10-25/100 cells showing staining), 2+ (25-SOcells/100) and 3+ {> 
50cells/1 00). 
Statistics 
The statistical analysis-including Pearson's chi-square test, Fisher's exact 
test, Kaplan-Meier survival curves and Mantei-Haenszel log rank test-was 
performed using the SPSS software (SPSS Inc, Chicago, USA). 
Results 
A total of 149 cases were studied. These comprised 127 (85.2o/o) women 
and 22 (14.8o/o) men; giving a male: female ratio of 1:5.8. The average age at 
surgery was 39.7 years, with a range from 13 to 77 years and median age of 37 
years. Ethnically, the majority were Malays (85.9o/o), followed by 19 Chinese 
(2.8o/o), 1 Indian (0.7o/o) and 1 Indonesian (0.7o/o). There were 50 cases of 
follicular adenomas, 66 nodular hyperplasias and 53 papillary carcinomas in this 
7 
study. Corresponding normal thyroid tissue from 74 of these cases served as 
controls. 
The age, sex and race distribution of cases in each of the groups were 
comparable to the overall figures stated above. 
For the papillary carcinoma group, the average age at surgery was 45. 1 
years, with the youngest patient being 20 years and the oldest 77 years. The 
duration of symptoms (noticeable neck swelling) was on average 50.9 months 
(4.2 years) with a range of 3 months to 30 years. The tumour size ranged from 
microscopic to 10 em in the widest diameter (replacing the whole thyroid). The 
median size was 20 mm with no correlation between size of the tumour and the 
duration of symptoms (P=0.971). 
The majority (64.1 o/o) of the patients presented with stage I disease 
(according to UICC staging of thyroid carcinoma16). Of these, histological 
examination showed evidence of vascular and lymphatic invasion in 4 cases, 
while 4 others showed capsular invasion. Two of the later had extra thyroidal soft 
tissue tumour extension. Eighteen of 53 patients had cervical lymph node 
metastasis at presentation. One case had bone and 2 cases had lung metastasis 
at presentation (in addition to nodal disease). 
The patients were followed up for an average 46.2 months with a range of 
1 month after surgery up to 10 years. Follow-up records were available for 43 
patients. For that period, 29 patients (67.4%) remained free of disease. Another 5 
(11.6o/o) patients were alive with recurrent disease; 1 (2.3°/o} patient died of 
8 
recurrent disease 3 years after the surgery and 4 (9.3o/o) patients died of other 
causes. 
Histologically, 16 of the papillary carcinomas co-existed with multinodular 
goitre and 3 co-existed with Hashimoto's (lymphocytic) thyroiditis. There were 8 
cases of microscopic papillary carcinoma, 5 of follicular variant, 2 tall cell variant 
and 1 encapsulated variant. One papillary carcinoma co-existed with follicular 
carcinoma. One of the cases showed features of anaplastic transformation. This 
particular patient presented with local recurrence and multiple lymph nodes 
metastases 15 months after surgery. 
RET immunohistochemistry 
The extent and intensity of staining varied among the groups. The majority of 
papillary carcinoma (23/53 cases) had a higher intensity of RET staining, 
involving a larger number of cells (Fig. 1). In contrast normal thyroid tissues, 
except 4 cases, were RET negative. Most of the RET -positive follicular 
adenomas and nodular hyperplasia cases showed less intense staining (Fig. 2 a, 
b). 
RET was detected in 66 cases. Four of the 74 samples (5.4o/o) of normal 
thyroid tissue were found to express RET. Among the follicular adenomas, 9 of 
50 (18o/o} were positive whilst 15 of 66 (22.7o/o) nodular hyperplasias showed 
positivity. The papillary carcinoma group had the highest proportion (71.7o/o) of 
positivity; P<0.001 (Fig. 3). 
The four normal thyroid tissues with RET positivity were associated with 
adjacent neoplasia; one follicular adenoma and three papillary carcinomas. 
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RET was localised in 9 of 50 { 18o/o) follicular adenomas, with no 
correlation of expression with sex (P=1.00) or age of the patients (P=1.00). Of 
the nodular hyperplasia cases, 15 of 66 (22. 7o/o) were RET positive. There was 
no significant differences in RET expression between sexes (P=0.188) and age 
groups, (P=0.444). 
Among the nodular hyperplasia cases with coexisting papillary carcinoma 
(11 cases), 8 (66.7%) cases were RET negative and 4 (33.3o/o) were positive 
(Table 1) (P=0.461). There was also no correlation between the size of the lesion 
and RET positivity {P=0.791). 
On the whole, RET was expressed in 38 of 53 papillary carcinoma cases 
(71.7o/o}. The staining pattern was diffuse in the cytoplasm and generally strong 
in intensity (23 cases having 3+ score). 
RET was detected in 17 of 23 classical type papillary carcinoma and in 4 
of 5 of the follicular variant. Both the tall cell variant carcinomas expressed RET. 
The carcinoma with anaplastic transformation also expressed RET. In this case, 
the well-differentiated area had strong diffuse staining, while the anaplastic 
quarter showed moderate focal staining. The encapsulated variant was negative. 
Two of the three cases with coexisting Hashimoto's thyroiditis expressed RET. 
Twelve of 19 (63.2o/o) of micropapillary carcinoma expressed RET. There were 
33 cases of overt papillary carcinoma, and RET was detected in 78.5o/o (25 of 33 
cases) (P=0.359). 
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There was no association between RET expression and age (P=0.149); 
duration of symptoms (P=0.329); gender (P=0.418} and size of the papillary 
carcinoma (P=0.721). 
No relationship was found between tumour aggressiveness and RET 
expression. Kaplan-Meier survival curve and log-rank test of significance showed 
no difference between the survivals of RET -positive tumour patients compared to 
negative tumours. 
p53 immunohistochemistry 
Overall, p53 staining was more evenly distributed among the follicular 
adenoma, nodular hyperplasia and papillary carcinoma groups (Fig. 4 a,b,c). It 
was completely negative in normal thyroid tissue. 
Of the 66 nodular hyperplasia cases studied, 11 cases (16.7o/o) showed 
p53 reactivity (Fig. 5), mostly of 1+ score. However, those 16 cases with co-
existing papillary carcinoma showed no p53 expression in the nodular 
hyperplasia area. 
Seven out of 50 ( 14o/o) cases of follicular adenoma were p53 positive 
{Fig. 5). Six of these cases were pure follicular adenomas and one other was 
oncocytic type. 
p53 was detected in 9 of 53 ( 17o/o) papillary carcinoma cases (Fig. 5). Six 
of them showed 2+ and three showed 1 + score. Six of p53 positive cases were 
papillary carcinoma of classical type. None of the follicular variant expressed 
p53. One of two of the tall cell variant was positive. The encapsulated variant 
was negative. All the tumours coexisting with Hashimoto's thyroiditis were also 
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p53 negative. As expected, the papillary carcinoma with anaplastic 
transformation was p53 positive. Two of 19 (10.5o/o) micropapillary carcinoma 
were p53 positive (P=0.458). 
Age, gender, duration of symptoms, and size of the papillary carcinoma 
did not have any significant correlation with p53 expression of the tumour cells 
(P=1.00; P=0.169; P=0.222; P=1.00 respectively) 
All the tumours with distant metastasis were p53 negative. However, more 
tumours with lymph node metastasis showed p53 positivity compared to the non-
metastasising group; P=0.048. Kaplan-Meier analysis and log rank test of 
significance showed that p53 was an excellent predictor of the ability of the 
tumour for capsular invasion and lymph node metastasis (Fig. 6). 
Survival curve and log-rank test of p53-positive and negative tumours 
showed that p53 was a significant prognostic factor in the survival of papillary 
carcinoma patients (Fig. 7). 
Association between RET and p53 expression 
To investigate the relationship between RET and p53 expression in these 
tumours, both the markers were analysed together. In all of the groups, there 
was no concordance between RET and p53 expression. 
Conclusion 
Our papillary carcinoma population is unusual in two respects: firstly, there is a 
possible association with nodular hyperplasia, and secondly they are mostly 
contained within the thyroid and not associated with early mortality. 
12 
The RET -positive group of all the truly benign cases may represent an early 
molecular event in the formation of papillary carcinoma; however, this is merely 
speculative at this point. RET -positive cells adjacent to a papillary carcinoma 
may be a clone of neoplastic cells not yet showing the malignant histological 
characteristics. 
The p53-positive RET -negative lesions may as likely end up as papillary 
carcinoma as any other type of malignancy e.g. follicular carcinoma etc. Further 
study of other mutations, for example: ras, p 16, c-emB2 and gsp genes are 
required in order to further predict the line of transformation. 
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Fig. 1 Immunohistochemical positivity for RET within papillary carcinoma, 
strong, diffuse staining is observed in most of the cases (x1 0). 
Fig. 2 RET immunohistochemistry in follicular adenoma (a: x10), and nodular 
hyperplasia (b: x10) showed weaker staining and patchy distribution (arrows). 
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Fig. 3 Summary of RET immunohistochemistry staining result for normal thyroid 
tissue, follicular adenoma, nodular hyperplasia (NH) and papillary carcinoma (PTC). 
There was a significantly higher number of RET positive cells in the papillary 
carcinoma group compared to the other 3 groups; P=0.001. 
17 
Fig. 4. p53 immunohistochemistry staining for follicular adenoma (a: x40) 
nodular hyperplasia (NH) (b: x40) and papillary carcinoma (PTC) (c: x40). 
The positive cells are marked by arrows. 
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Fig. 5 Summary of p53 expression among the different groups of 
cases, normal thyroid, follicular adenoma, nodular hyperplasia 
(NH) and papillary carcinoma (PTC). 
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Capsular invasion and metastatic risk 
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Fig. 6 Kaplan-Meier curve and log rank comparison of relative risk of lymph 
node metastasis and capsular invasion by p53 positive and negative tumours. 
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Fig. 7 Kaplan-Meier curve and log rank comparison of disease specific survival 
and tumour recurrence in p53 positive and negative tumours. 
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TABLE 1 Summary of RET expression in nodular hyperplasia with and without 
associated papillary carcinoma. 
Nodular hyperplasia Number of cases and its Total 
percentage 
RET negative RET positive 
Without papillary carcinoma 39 78o/o "11 22 °/o 50 
With papillary carcinoma 8 66.7% 4 33.3% 12 
lfotal 47 15 62 
NB: Fisher's exact test, P= 0.461 
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Immunohistochemical localisation of RET and p53 mutant protein of 
thyroid lesions in a North-Eastern Malaysian population and its 
prognostic implications ·· 
EFFA:T 0MAR, MANOHARAN MADHAVAN AND NoR HAYATI OTHMAN 
Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia 
Summary the widest cut surface as well as other solid nodules 
Aims: To investigate RET and p53 expression in local (number of blocks ranged from 4 to 10 blocks per 
thyroid lesions, in order to shed light on the pathogenesis of specimen), revealed co-existing carcinoma in 34% of 
papillary carcinoma and explain the high prevalence of this cases.2 This is very high in comparison with other 
condition among the nodular hyperplasia (multi-nodular international series of sporadic goitre where only 4-17% 
goitre) cases. of the glands were found to harbour carcinomas.3 
Methods: Archival thyroid tissue was retrieved from Hospital Papillary carcinoma of the thyroid has no identifiable 
Universiti Sains Malaysia (HUSM) Pathology Department precursor lesion to date, compared with follicular 
files and studied by immunohistochemistry for RET and p53 carcinoma, which is linked to follicular adenoma.4 In 
mutant protein. Normal tissues from 74 cases served as addition, the ret/papillary-thyroid-carcinoma (PTC) onco-
controls. gene, which was discovered relatively recently, is found to 
Results: Fifty follicular adenoma, 66 nodular hyperplasia and be associated with only papillary carcinoma.5 Most studies 
53 papillary carcinoma cases were studied. RET was have found that no other follicular cell tumour expresses 
expressed in 5.4% of normal thyroid tissue, 18% of follicular it.5- 7 The ret proto-oncogene encodes a member of the 
adenomas, 22.7% of nodular hyperplasia cases and 71 .7% tyrosine kinase family of transmembrane receptors and has 
of papillary carcinomas. Its expression in papillary carci- been mapped to the region of chromosome 10qll.2.8•9 It 
noma was not associated with the coexistence of nodular consists of 21 exons, 10 spanning more than 60 kb of 
hyperplasia lesions. p53 was expressed by 17% of papillary genomic DNA and encodes five major mRNA species. The 
carcinomas. No association was found between p53 proto-oncogene products are expressed as polypeptides of 
expression of nodular hyperplasia with or without co-existing 1072 and 1114 amino acid residues that differ in C-
papillary carcinoma. p53, rather than RET, was an excellent terminal amino acid composit ion. 10 The ret protein is a 
predictor of tumour lymph node metastasis and capsular receptor for a glial cell line-derived neurotrophic factor 
invasion. p53 was also a significant prognosticator of that is normally expressed in neuroendocrine cells and also 
survival outcome. tumours of these cells.5 It is not present in the normal 
Conclusions: RET expression is highly prevalent in local thyroid follicular cells.4 
papillary carcinoma, indicating a significant role in the Sporadic papillary carcinoma of the thyroid is asso-
pathogenesis of this tumour, with no apparent role in tumour ciated with somatic rearrangement o f the ret gene. 11 This 
behaviour and survival outcome. p53 o n the other hand type of PTC-specific mutation was first described in a 
appears to be a significant factor in the latter events. The lymph node with metastatic papillary thyroid carcinoma. 11 
two genes appear to act in two different pathways: the Consequent analyses revealed the three most frequent 
former being an initiator, and the later a .propagator of _ forms ~f~~~~/PTC rearrangement, known as ret!PTC-1 ~"2, 
papillary carcinoma. - and -3. · · 
p53 is a well-studied tumour suppressor gene, located on 
Key words: Thyroid, nodular hyperplasia, neoplasia, RET, ret/PTC, p53, -- chr?mo.some 17p ~ 3. 1. I.ts mutation has been reported 
immunohistochemistry. mamly m anaplastic carcmoma, frequently involving exons= 
s. -8.4 H ow. ever, in. a recently published study employing Received 22 April, revised 9 September, accepted 29 October 2003 1mmunohtstochem1stry, mutant p53 protein was detectee-
_ __,..,_- in papillary carcinoma, as well as in follicular carcinoma. l<r 
The wild-type p53 protein has a short half-life, whereas 
INTRODUCTION t?e mutate~ protein r~mains ':"ithin the cells for a longer 
f he development of a malignant lesion in a long-standing ttme, a.llow.mg detectiOn by Immunohistochemistry. p53 
Jre-existing benign condition has been documented ror - expressiOn m papillary and follicular carcinoma has -bee 
nany tur~ours, ~ncluding t~yroid carcinoma: 1 A st~dy ?~ correlated with aggressiveness, as evidenced by th~ 
lOO thyrotd sp~c1mens subm1tted to the Hosp1tal Umvers1tl pre~e.nce of extra-thyroidal tumour extension in _ 53_ )ains Malays1a (HUSM) Pathology Department from pOSitive tumours. 14 p 
. 990 to 1995 revealed that multi-nodular goitre is the most The question is whether we have at last found 1· bl 
. E . . f h I . d I a re Ia e :o~mon lesiOn. xamm~t10n o. t ese mu tk1-no fu ar marker (ret/P-r:C) to detect follicular cells with mutatiOns 
~01 tres, where representative sect10ns were ta en rom that progress mto papillary carcinoma. If so, then is it 
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.;sible that the high incidence of papillary carcinoma 
;een in the nodular hyperplasia population is due to 
:tctivation of this ret!PTC oncogene? 
We were also interested in whether there is any 
1ssociation between p53 and ret gene expression, and 
f these markers are useful in predicting a malignant 
·.ransformation fn a benign lesion. We further investigated 
he usefulness of p53 and retiPTC in predicting aggres-
,iveness of papillary carcinoma, and compared them to 
Lssess them as predictors of survival. 
The answers to these questions are important, first in 
mravelling the pathogenesis of the papillary carcinoma in 
1ur locality and, second, in identifying the patients who 
.re more likely to develop aggressive disease, making it 
1ossible for clinicians to tailor each patient's treatment, 
~us avoiding over- or under-treatment. 
~ATERIALS AND METHODS 
faterials 
rchival blocks of thyroid tissue from 1990 to 2000, which had been 
stologically diagnosed as multi-nodular goitre (nodular hyperplasia), 
llicular adenoma and papillary carcinoma, were retrieved from the 
gistry of HUSM Pathology Department, Kelantan, Malaysia. 
'inical data 
1e clinical data of the patients, including age, sex and race, were 
:orded. Duration of s~ptoms for papillary carcinoma (visible neck 
•elling), size of tumour, duration of follow-up and survival character-
ics (tumour recurrence, death due to disease or other causes) were 
tained from the patients' medical records. 
stology 
1 histological materials from the selected cases were reviewed by one of 
:authors (EO) to confirm that the diagnosis was in accordance with the 
ommendations of the World Health Organization. The presence of 
lph node metastasis, capsular and extra-thyroidal invasion, as well as 
:cular and lymphatic invasion were determined histologically. 
Statistics 
The statistical analysis-including Pearson's chi-square test, Fisher's exact 
test, Kaplan-Meier survival curves and Mantel-Haenszel log rank test-
was performed using SPSS software (SPSS Inc., USA). 
RESULTS 
A total of 149 cases were studied. These comprised 127 
(85.2%) women and 22 (14.8%) men, giving a male-female 
ratio of 1:5.8. The average age at surgery was 39.7 years, 
with a range from 13 to 77 years and a median age of 37 
years. Ethnically, the majority were Malays (85.9%), 
followed by 19 Chinese (2.8%), one Indian (0.7%) and 
one Indonesian (0. 7%). There were 50 cases of follicular 
adenomas, 66 nodular hyperplasias and 53 papillary 
carcinomas in this study. Corresponding normal thyroid 
tissue from 74 of these cases served as controls. 
The age, sex and race distribution of cases in each of the 
groups were comparable with the overall figures stated 
~ov~ . 
For the papillary carcinoma group, the average age at 
surgery was 45.1 years, with the youngest patient being 20 
years and the oldest 77 years. The duration of symptoms 
(noticeable neck swelling) was on average 50.9 months (4.2 
years) with a range of 3 months to 30 years. The tumour 
size ranged from microscopic to 1 0 em in the widest 
_ diameter (replacing the whole thyroid). The median size 
was 20 mm with no correlation between size of the tumour 
and the duration of symptoms (P=0.971). 
The majority (64.1 °/o) of the patients presented with 
stage I disease (according to UICC staging of thyroid 
carcinoma16). Of these, histological examination showed 
evidence of vascular and lymphatic invasion in four cases, 
while four others showed capsular invasion. Two of the 
latter had extra thyroidal soft tissue tumour extension. 
Eighteen of 53 patients had cervical lymph node metastasis 
at presentation. One case had bone and two cases had lung 
metastasis at presentation (in addition to nodal disease). 
The patients were followed up for an average 46.2 
months with a range of 1 month after surgery up to 10 
nunohistochemistry for RET __ years. Follow-up records were available for 43 patients. 
bl k Ctl·oned at 3 J.Ull thickness and applied to poly-1-lysin For that period, 29 patients (67.4%) remained free of sue oc s were se -==- -. h fi ( o ) · • · 
. t d J'des. Endogenous peroxidase quenching was carried out by __:3:_dtsease. Anot er ve 11.6% patients were ahve With 
coa e s 1 - ._.....- d' (2 3o/) · d' d f Libation with 3% hydrogen peroxide in methanol. Immunohistochem-. = ~ecurrent tsease; one . "o pattent te o recurrent 
y for RET was performed using a rabbit polyclonal ant~body against_.==:-d!sease 3 years after the surgery, and four (9.3%) patients 
carboxy terminal region of RET (C-19; Santa Cruz Biotechnology,_: ._:~~led from other causes. 
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A.) at a dilution of 1:100 at room temperature for 2 h or at 4oc for 16 h. _:::.:_ Histologically, 16 of the papillary carcinomas co-existed 
treptavidin-avidin-biotin complex (Dako, Denmark) detection system -~Jth multi-nodular goitre and three co-existed with _ ·~ 
used with diaminobenzidine employed as the subs~rate .. The exte~t of ~a_shimoto's (lymphocytic) thyroiditis. There were eight e-
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nsity). Only cytoplasmic stammg was noted. - - -~.:·--~oma. One of the cases showed features of anaplastic ------ --~ 
.--·=~~ltansformation. This particular patient presented with __ 
tunohistochemistryfor p53 protein - -- ---- . _-_:;;:;:tocal recurrence and multiple lymph nodes metastasesl5 ·-== 
was detected using a commercial monoclonal antibody (Dako, D0-7) _ ~~ ullionths after surgery. . - . !_ 8 
a dilution of 1 :SO incubated at room temperature for 2 h.·. A ~- -- _________ _ 
Jtavidin-avidin-biotin complex (Dako) detection system was wed-- -RET . h. t h . t 
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nucleus of the cells. One hundred cells were counted and the number :·.::...,The extent and mtens1ty of stamt~g varied among the 
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tivity was scored as 1 + (10-251100 cells showing staining), 2+ c ·:=had a higher intensity of RET staining, involving a larger 
so cells/100) and 3+ (>50 cells/100). ~number of cells (Fig. 1). By contrast, normal thyroid 
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